scholarly journals Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index

2012 ◽  
Vol 107 (11) ◽  
pp. 1815-1819 ◽  
Author(s):  
M A N Sendur ◽  
S Aksoy ◽  
N Zengin ◽  
K Altundag
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Aromatase Inhibitor ◽  
Cancer Patients ◽  
Body Mass ◽  
Hormone Receptor ◽  
Postmenopausal Breast Cancer ◽  
The Body ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive

scholarly journals Assessment of cardiotoxicity in hormone positive postmenopausal breast cancer patients receiving aromatase inhibitors

2019 ◽  
Vol 9 (1) ◽  
pp. 11
Author(s):  
Reham M. Faheim ◽  
Eman A. El-Shaarawy ◽  
Dina A. Salem ◽  
Rehab G. Shaaban
Keyword(s):  
Breast Cancer ◽  
Blood Pressure ◽  
Lipid Profile ◽  
Cancer Patients ◽  
Aromatase Inhibitors ◽  
Hormone Receptor ◽  
Postmenopausal Breast Cancer ◽  
P Value ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive

Background: Aromatase inhibitors (AIs) represent an effective endocrine treatment for hormone receptor-positive postmenopausal breast cancer patients with early stage or metastatic disease.Objective: Assessment of Cardiotoxicity in Hormone positive Postmenopausal Breast Cancer Patients receiving AIs (upfront orswitch therapy).Methods: This cross sectional study included 123 postmenopausal breast cancer patients presented to the Clinical Oncology Department, Ain Shams University (Cairo, Egypt) in the interval from August 2016 to June 2017 with hormone receptor positive receiving Aromatase Inhibitors, To assess cardiotoxicity in these patients, they were subjected to blood pressure and lipid profile measurement, electrocardiography (ECG), and electrocardiography (ECHO) and classified into patients had Nolvadex then A.I (arm 1) and others had upfront A.I (arm 2).Results: The age of patients ranged from 41 years to 85 years with mean age of 61 years. Seventy one patients (57.7%) showed cardiotoxicity as assessed by ECHO. They showed significant correlation with rising age above 62 years, IHD, history of HTN and DM (p value: .001, .001, .017 and 0.035 respectively). However, correlation between cardiotoxity and blood pressure changes, lipid profile changes and ECG findings and ECHO changes in switch therapy and upfront A.I were not statistically significant (p value = .275, .116, .081 and .761 respectively).Conclusion: Assessment of cardiotoxicity in hormone positive postmenopausal breast cancer patients receiving Aromatase Inhibitors showed evidence of cardiotoxicity in half the patients (57.7%) as detected by ECHO only. They showed statistically non significant correlations either recievied switch therapy or upfront A.I.

scholarly journals Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study

2016 ◽  
Vol 16 (2) ◽  
pp. 165-175 ◽  
Author(s):  
Carolin C. Hack ◽  
Peter A. Fasching ◽  
Tanja Fehm ◽  
Johann de Waal ◽  
Mahdi Rezai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Integrative Medicine ◽  
Hormone Receptor ◽  
Postmenopausal Breast Cancer ◽  
Considerable Proportion ◽  
Medical Conditions ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive ◽  
Noninterventional Study

Background. Breast cancer patients often use complementary and alternative medicine, but few prospectively collected data on the topic are available specifically for postmenopausal breast cancer patients. A large prospective study was therefore conducted within a noninterventional study in order to identify the characteristics of patients interested in integrative medicine. Methods. The EvAluate-TM study is a prospective, multicenter noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor–positive primary breast cancer. Between 2008 and 2009, 5045 postmenopausal patients were enrolled at 339 certified breast centers in Germany. As part of the data collection process, patients were asked at the baseline about their interest in and information needs relating to integrative medicine. Results. Of the 5045 patients recruited, 3411 responded to the questionnaire on integrative medicine and took part in the analysis, 1583 patients expressed an interest in integrative medicine, and 1828 patients declared no interest. Relevant predictors of interest in integrative medicine were age, body mass index, tumor size, previous chemotherapy, and use of concomitant medications for other medical conditions. Interest in integrative medicine declined highly significantly ( P < .001) with age (<50 years, 74.1%; 50-60 years, 54.1%; >65 years, 38.0%). Patients in favor of integrative medicine were significantly less satisfied with the information received about individual treatments and antihormonal therapy. Patients with interest in integrative medicine were more often interested in rehabilitation and fitness, nutritional counseling, and additional support from self-help organizations. These women were mostly interested in receiving information about their disease and integrative medicine from a physician, rather than from other sources. Conclusions. This study shows that a considerable proportion of postmenopausal breast cancer patients are interested in integrative medicine. Information about integrative medicine should therefore be provided as part of patient care for this group. It was found that receiving concomitant medication for other medical conditions is one of the main predictors for women not being interested in integrative medicine. This group of patients may need special attention and individualized information about integrative medicine. Additionally, most patients were interested in obtaining the relevant information from their doctor.

Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients

2020 ◽  
Vol 20 (1) ◽  
pp. e89-e98 ◽  
Author(s):  
Luca Cantini ◽  
Mirco Pistelli ◽  
Filippo Merloni ◽  
Andrea Fontana ◽  
Ilaria Bertolini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Cancer Patients ◽  
Body Mass ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Recurrence Risk ◽  
Hormone Receptor Status ◽  
Breast Cancer Patients ◽  
Her2 Positive

The body mass index (BMI) and the effectiveness of the fulvestrant as treatment postmenopausal metastatic breast cancer patients

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S66
Author(s):  
A. Jagiello-Gruszfeld ◽  
I. Lemanska ◽  
A. Gorniak ◽  
M. Kunkiel ◽  
E. Glinka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Body Mass ◽  
Metastatic Breast ◽  
The Body ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document